Scilex Holding Preliminary Q1 Net Sales For ZTlido Were $12M-$13M; Q1 Gross Sales For ZTlido Were $34M-$38M; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
Scilex Holding Preliminary Q1 Net Sales For ZTlido Were $12M-$13M; Q1 Gross Sales For ZTlido Were $34M-$38M; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today provided certain preliminary unaudited financial results for gross and net sales for ZTlido for the quarter ended March 31, 2024, and proposed plans to reduce research and development and other administrative expenses in 2024.
Scilex Holding Company（納斯達克股票代碼：SCLX，“Scilex” 或 “公司”）））））是一家專注於收購、開發和商業化用於治療急慢性疼痛的非阿片類疼痛管理產品的創新型創收公司，今天公佈了截至2024年3月31日的季度中ZTLido總銷售額和淨銷售額的某些未經審計的初步財務業績，並提出了減少研發的計劃 2024年的其他管理費用。
The Company estimates that:
該公司估計：
- ZTlido gross sales for the first quarter of 2024 were in the range of $34.0 million to $38.0 million, compared to $27.5 million for the first quarter of 2023, representing growth in the range of approximately 24% to 38%.
- ZTlido net sales for the first quarter of 2024 were in the range of $12.0 million to $13.0 million, compared to $10.6 million for the first quarter of 2023, representing growth in the range of approximately 13% to 23%.
- ZTLido2024年第一季度的總銷售額在3,400萬美元至3,800萬美元之間，而2023年第一季度的總銷售額爲2750萬美元，增長幅度約爲24％至38％。
- ZTLido2024年第一季度的淨銷售額在1,200萬美元至1,300萬美元之間，而2023年第一季度爲1,060萬美元，增長約13％至23％。
This preliminary financial data has been prepared by and is the responsibility of Scilex. Scilex has not fully completed its review of these preliminary financial results for the quarter ended March 31, 2024. Scilex's independent auditor has not reviewed or audited these preliminary estimated financial results. Scilex's actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges.
該初步財務數據由Scilex編制並由Scilex負責。Scilex尚未完全完成對截至2024年3月31日的季度初步財務業績的審查。Scilex的獨立核數師尚未審查或審計這些初步的估計財務業績。Scilex的實際業績可能與這些初步財務業績存在重大差異，並且可能超出估計範圍。
"We believe the non-opioid pain management prescription market is adopting our products rapidly and should be reflected in continued sales growth, both within the traditional neuropathic pain and migraine non-opioid market and from the additional potential launch of our new gout prophylaxis product, Gloperba expected to launch in the first half of 2024. Scilex also plans to reduce R&D and other administrative expenses and to focus on its late-stage pipeline programs such as SP-102. This will enable us to invest in expanding the commercial and production activity for our products. Our intention is to drive value creation and ensure we remain ahead of rising demand for our non-opioid products."
“我們認爲，非阿片類疼痛管理處方市場正在迅速採用我們的產品，這應反映在傳統神經病理性疼痛和偏頭痛非阿片類藥物市場的持續銷售增長上，以及我們的新痛風預防產品Gloperba預計將於2024年上半年推出。Scilex還計劃減少研發和其他管理費用，並將重點放在後期管道項目上，例如 SP-102。這將使我們能夠投資擴大我們產品的商業和生產活動。我們的意圖是推動價值創造，確保我們在非阿片類藥物產品不斷增長的需求中保持領先地位。”
Scilex has been working with its co-pay savings card adjudicators to resolve the recent breakdown of processing of insurance claims by Change Healthcare, following a cyber-attack on Change Healthcare. Scilex is aware of the impact this disruption has had on its patients and customers and has worked diligently to resolve the issue. As of today, co-pay savings card processing for ZTlido has been restored to normal operations.
在Change Healthcare遭到網絡攻擊之後，Scilex一直在與其自付儲蓄卡裁定人合作，以解決Change Healthcare最近發生的保險索賠處理中斷的問題。Scilex意識到這種中斷對其患者和客戶的影響，並一直在努力解決這個問題。截至今天，ZTLido的自付儲蓄卡處理已恢復正常運營。
譯文內容由第三人軟體翻譯。